Literature DB >> 12095809

Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin.

Richard F Spaide1, Melissa L Martin, Jason Slakter, Lawrence A Yannuzzi, John Sorenson, David R Guyer, K Bailey Freund.   

Abstract

PURPOSE: To report the effects of photodynamic therapy using verteporfin in the treatment of patients with subfoveal idiopathic choroidal vascularization (CNV).
DESIGN: Interventional case series.
METHODS: In a retrospective study, eight eyes of eight consecutive patients aged 55 years or younger with subfoveal idiopathic CNV treated with photodynamic therapy using verteporfin were evaluated. Visual acuity was considered to be improved if the visual angle was halved, while acuity was thought to be worse if the visual angle doubled.
RESULTS: The eight patients included three men and five women with a mean (+/- SD) age of 34.6 (+/- 9.7) years (range 25-53 years). The mean follow-up time was 13.5 months. At the end of the follow-up period the visual acuity improved in five eyes (62.5%), remained unchanged in one (12.5%), and decreased in two (25%). The mean acuity improvement was 3.6 lines of Snellen acuity by the end of the follow-up period, a change that was statistically significant (P =.027, Wilcoxon signed-rank test). No patient had any complication from the treatment.
CONCLUSIONS: There is no widely accepted method for treating subfoveal idiopathic CNV and all previously investigated methods have had a significant number of serious side effects. Although the follow-up time and the number of patients in this pilot study were limited, the encouraging results and lack of complications suggest that further study is indicated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095809     DOI: 10.1016/s0002-9394(02)01452-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  15 in total

1.  Photodynamic therapy: a treatment option in choroidal neovascularisation secondary to punctate inner choroidopathy.

Authors:  S Chatterjee; J M Gibson
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

2.  Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases.

Authors:  Joachim Wachtlin; Heinrich Heimann; Tim Behme; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-11       Impact factor: 3.117

3.  [Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization. Two-year results].

Authors:  J Wachtlin; A Wehner; H Heimann; M H Foerster
Journal:  Ophthalmologe       Date:  2004-05       Impact factor: 1.059

4.  Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation.

Authors:  Alfonso Giovannini; Piergiorgio Neri; Lucia Mercanti; Claudia Bruè
Journal:  Br J Ophthalmol       Date:  2007-01-03       Impact factor: 4.638

5.  Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy.

Authors:  Noémi Maár; Erdem Ergun; Alexandra Luksch; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

Review 6.  25th RCOphth Congress, President's Session paper: 25 years of progress in medical retina.

Authors:  J M Gibson
Journal:  Eye (Lond)       Date:  2014-07-04       Impact factor: 3.775

7.  Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy.

Authors:  H Imai; S Honda; Y Nakanishi; H Yamamoto; Y Tsukahara; A Negi
Journal:  Br J Ophthalmol       Date:  2006-07-06       Impact factor: 4.638

8.  Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression.

Authors:  T Leslie; N Lois; D Christopoulou; J A Olson; J V Forrester
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

9.  Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan.

Authors:  Shigeru Honda; Yasuo Kurimoto; Yasuaki Kagotani; Hiroyuki Yamamoto; Hitoshi Takagi; Mamoru Uenishi
Journal:  Jpn J Ophthalmol       Date:  2009-12-18       Impact factor: 2.447

10.  Photodynamic therapy with verteporfin for chronic central serous choroidoretinopathy and idiopathic choroidal neovascularization-first report from the sultanate of oman.

Authors:  Upender Krishen Wali; Nadia Al-Kharousi; Harith Hamood
Journal:  Oman Med J       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.